|8.61||-0.3300||-3.69%||Vol 107.74K||1Y Perf 35.77%|
|Apr 16th, 2021 09:53 DELAYED|
|- -%||- -|
|Target Price||18.40||Analyst Rating||Strong Buy 1.00|
|Potential %||105.82||Finscreener Ranking||★★★★ — 54.00|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★+ 44.40|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★+ — 57.85|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Market Cap||491.99M||Earnings Rating||Buy|
|Price Range Ratio 52W %||34.24||Earnings Date||21st May 2021|
Today's Price Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||21st May 2021|
|Estimated EPS Next Report||-0.49|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||578.76K|
|Avg. Monthly Volume||804.56K|
|Avg. Quarterly Volume||1.01M|
Precision BioSciences Inc. (NASDAQ: DTIL) stock closed at 8.94 per share at the end of the most recent trading day (a 2.64% change compared to the prior day closing price) with a volume of 561.52K shares and market capitalization of 491.99M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 223 people. Precision BioSciences Inc. CEO is Matthew Kane.
The one-year performance of Precision BioSciences Inc. stock is 35.77%, while year-to-date (YTD) performance is 7.19%. DTIL stock has a five-year performance of %. Its 52-week range is between 4.45 and 16.6, which gives DTIL stock a 52-week price range ratio of 34.24%
Precision BioSciences Inc. currently has a PE ratio of -4.30, a price-to-book (PB) ratio of 11.43, a price-to-sale (PS) ratio of 27.56, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -53.66%, a ROC of -89.60% and a ROE of -111.79%. The company’s profit margin is -%, its EBITDA margin is -443.10%, and its revenue ttm is $17.29 Million , which makes it $0.30 revenue per share.
Of the last four earnings reports from Precision BioSciences Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.49 for the next earnings report. Precision BioSciences Inc.’s next earnings report date is 21st May 2021.
The consensus rating of Wall Street analysts for Precision BioSciences Inc. is Strong Buy (1), with a target price of $18.4, which is +105.82% compared to the current price. The earnings rating for Precision BioSciences Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Precision BioSciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Precision BioSciences Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 11.98, ATR14 : 1.03, CCI20 : -75.64, Chaikin Money Flow : -0.12, MACD : -0.83, Money Flow Index : 49.55, ROC : -5.40, RSI : 50.52, STOCH (14,3) : 26.42, STOCH RSI : 1.00, UO : 36.62, Williams %R : -73.58), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Precision BioSciences Inc. in the last 12-months were: Abid Ansari (Option Excercise at a value of $22 115), David Thomson (Sold 10 000 shares of value $164 900 ), Derek Jantz (Option Excercise at a value of $6 884), Derek Jantz (Sold 68 677 shares of value $799 468 ), Matthew Kane (Option Excercise at a value of $9 466), Matthew Kane (Sold 107 323 shares of value $1 277 259 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.